Dexcom (DXCM) Change in Accured Expenses (2010 - 2026)

Dexcom (DXCM) has 17 years of Change in Accured Expenses data on file, last reported at $145.1 million in Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at $145.1 million, up 24283.33% year-over-year; the trailing twelve-month figure through Mar 2026 was $492.7 million (up 492600.0% YoY), and the FY2025 annual result was $347.0 million, up 678.33% from the prior year.
• Change in Accured Expenses rose to $145.1 million in Q1 2026 per DXCM's latest filing, from -$10.1 million in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $341.8 million in Q3 2025 and troughed at -$60.7 million in Q1 2024.
• A 5-year average of $45.0 million and a median of $9.4 million in 2022 frame the typical range for Change in Accured Expenses.
• The sharpest annual moves came in 2025 and 2026: Change in Accured Expenses tumbled 334.88% in 2025, then surged 24283.33% in 2026.
• A 5-year view of Change in Accured Expenses shows it stood at $123.8 million in 2022, then plunged by 83.36% to $20.6 million in 2023, then slumped by 79.13% to $4.3 million in 2024, then slumped by 334.88% to -$10.1 million in 2025, then soared by 1536.63% to $145.1 million in 2026.
• Business Quant data shows DXCM's Change in Accured Expenses at $145.1 million in Q1 2026, -$10.1 million in Q4 2025, and $341.8 million in Q3 2025.